CARB-X (Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator) and the Cystic Fibrosis Foundation has awarded a total of US$17.1 million to Microbion to advance the development of inhaled pravibismane for the treatment of chronic respiratory infections in patients with cystic fibrosis. The funding from CARB-X and Cystic Fibrosis Foundation will enable Microbion to complete preclincal and Phase 1 studies. 

Microbion’s projects have also been supported by non-dilutive grant funding from institutions such as the US Department of Defense and the National Institutes of Health.

Business Development 

We are actively seeking potential collaborations to explore the therapeutic potential of our technology in the treatment of serious infectious diseases on a global basis.

Please email us at bd@microbioncorp.com to discuss partnering opportunities.

Microbion Policies

Indirect Costs Policy